| Parameters |
ACE genotypes |
T-test |
| |
II |
ID/DD |
t |
P-value |
| Age (years) |
52.9 ± 1.2 |
53.3 ± 2.5 |
0.72 |
0.47 |
| Duration (years) |
5.9 ± 3.9 |
6.4 ± 4.8 |
0.36 |
0.71 |
| Fasting blood glucose (mg/dl) |
225.8 ± 17.8 |
240.9 ± 33.2 |
1.70 |
0.09 |
| 2-h PP blood glucose (mg/dl) |
301 ± 84.4 |
315 ± 47.3 |
0.75 |
0.45 |
| HDL (mg/dl) |
47.5 ± 6.5 |
43.3 ± 8.8 |
1.70 |
0.09 |
| TAG (mg/dl) |
171 ± 43.1 |
195.5 ± 55.4 |
1.55 |
0.12 |
| TC (mg/dl) |
234.5 ± 42.8 |
281 ± 45.7 |
3.42 |
0.001* |
| LDL (mg/dl) |
195.5 ± 36.2 |
228.7 ± 49.1 |
2.40 |
0.01* |
| Fasting insulin (μIU/ml) |
9.1 ± 4.5 |
13.1 ± 5.6 |
2.49 |
0.01* |
| HOMA-IR |
6.1 ± 3.3 |
6.5 ± 4.2 |
0.33 |
0.73 |
| Urinary Albumin/Creatinine ratio (UACR , mg/g) |
37.9 ± 4.6 |
40.5 ± 5.8 |
1.57 |
0.12 |
| Urea (mg %) |
47.4 ± 14.8 |
49.9 ± 17.2 |
0.50 |
0.61 |
| Serum creatinine (mg/dl) |
0.93 ± 0.45 |
0.98 ± 0.33 |
0.44 |
0.65 |
| estimated GFR (eGFR ,ml/min per 1.73m2 ) |
88.26 ± 49.1 |
81.33 ± 27.9 |
0.63 |
0.52 |
| sRAGE, pg/mL |
4450 ± 311 |
4667 ± 367 |
2.04 |
0.04* |
| Pentosidineng/ml |
249 ± 37 |
285 ± 46 |
2.73 |
0.008* |
| AOPP(μmol/l) |
178 ± 8.7 |
189 ± 3.4 |
6.45 |
<0.001* |
| Data presented as means ± SD. P was calculated by T-test. P was considered significant at <0.05.;*Significant HOMA-IR: Homeostatic Model Assessment of Insulin Resistance, sRAGE: soluble receptor for advanced glycation end-products, AOPP:advanced oxidation protein products |
|
